what are glp-1 agonists New Guidelines for Type 2 Diabetes in 2025 GLP-1 Receptor Agonist Shortage: Challenges

Heidenreich et al., 2022

Populations most likely to benefit include individuals with obesity or central adiposity, insulin resistance or type 2 diabetes, metabolic dysfunctionassociated fatty liver disease, or elevated cardiovascular risk

Studies have shown that weight loss can dramatically lower the risk of complications associated with obesity

Offer subcutaneous semaglutide up to 1 mg once weekly for CV, renal and glycaemic benefits (no specific guidance on tirzepatide or oral semaglutide because CVOT results were unavailable at time of review)

Eight cases with clinical and immunological characterization

These findings indicate that baseline muscle reserve may influence adaptive stability under chronic energy flux constriction